Patents by Inventor Michael GANTIER

Michael GANTIER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • OLIGONUCLEOTIDES
    Publication number: 20240287510
    Abstract: The present invention relates to oligonucleotides that maintain a Toll-Like Receptor 7 (TLR7) response and/or which potentiate Toll-Like Receptor 8 (TLR8) sensinq.
    Type: Application
    Filed: June 22, 2023
    Publication date: August 29, 2024
    Applicant: HUDSON INSTITUTE OF MEDICAL RESEARCH
    Inventor: Michael GANTIER
  • Methods for the treatment of inflammation associated with infection
    Patent number: 11541030
    Abstract: The present invention provides methods of treating inflammation associated with infection, and methods of preventing or reducing the severity of sepsis caused by inflammation associated with infection, in an individual comprising, consisting essentially of or consisting of the steps of administering a therapeutically effective amount of idronoxil, or derivative, pharmaceutically acceptable salt, ester, amide, polymorph and/or prodrug thereof to the individual, wherein the individual is diagnosed with, or suspected of having, early stage organ damage caused by inflammation associated with infection.
    Type: Grant
    Filed: May 19, 2021
    Date of Patent: January 3, 2023
    Assignee: NOXOPHARM LIMITED
    Inventors: Graham Kelly, Olivier Laczka, Michael Gantier
  • METHODS FOR THE TREATMENT OF INFLAMMATION ASSOCIATED WITH INFECTION
    Publication number: 20210299085
    Abstract: The present invention provides methods of treating inflammation associated with infection, and methods of preventing or reducing the severity of sepsis caused by inflammation associated with infection, in an individual comprising, consisting essentially of or consisting of the steps of administering a therapeutically effective amount of idronoxil, or derivative, pharmaceutically acceptable salt, ester, amide, polymorph and/or prodrug thereof to the individual, wherein the individual is diagnosed with, or suspected of having, early stage organ damage caused by inflammation associated with infection.
    Type: Application
    Filed: May 19, 2021
    Publication date: September 30, 2021
    Applicant: NOXOPHARM LIMITED
    Inventors: Graham KELLY, Olivier LACZKA, Michael GANTIER